Madrigal Pharmaceuticals (MDGL) PT Raised to $536 at BofA Securities
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Price: $528.10 +2.67%
Rating Summary:
20 Buy, 4 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Rating Summary:
20 Buy, 4 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Join SI Premium – FREE
BofA Securities analyst Jason Zemansky raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $536.00 (from $529.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Ribo and Madrigal hit first milestone in siRNA MASH drug program
- HCL Technologies (HCLT:IN) PT Lowered to INR1,110 at BNP Paribas Exane
- Kardex AG (KARN:SW) PT Raised to CHF348 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
